600479.SH
千金药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.80
+0.41%Year over year
Reported trailing growth
- Revenue
- -1.1%
- EBITDA
- —
- EBIT
- +33.4%
- EPS
- +24.1%
- Free cash flow
- -10.8%
- Operating cash flow
- +13.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.4%
- EBITDA
- +0.1%
- EBIT
- -0.5%
- Net income
- -1.8%
- EPS
- -2.0%
- Free cash flow
- -20.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026